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Abstract
Background: Microscopic colitis presents with similar symptoms to classic inflammatory bowel diseases.
Osteoporosis is a common complication of Crohn’s disease but there are no data concerning bone metabolism in
microscopic colitis.
Aims: The aim of the present study was to evaluate bone density and metabolism in patients with microscopic
colitis.
Methods: Fourteen patients microscopic colitis were included in the study, and 28 healthy persons and 28 age
and gender matched Crohn’s disease patients were enrolled as controls. Bone mineral density was measured using
dual x-ray absorptiometry at the lumbar spine, femoral neck and the radius. Serum bone formation and bone
resorption markers (osteocalcin and beta-crosslaps, respectively) were measured using immunoassays.
Results: Low bone mass was measured in 57.14% patients with microscopic colitis. Bone mineral density at the
femoral neck in patients suffering from microscopic colitis and Crohn’s disease was lower than in healthy controls
(0.852 ± 0.165 and 0.807 ± 0.136 vs. 1.056 ± 0.126 g/cm2; p < 0.01). Bone mineral density at the non-dominant
radius was decreased in microscopic colitis patients (0.565 ± 0.093 vs. 0.667 ± 0.072 g/cm2; p < 0.05) but
unaffected in Crohn’s disease patients (0.672 ± 0.056 g/cm2). Mean beta-crosslaps concentration was higher in
microscopic colitis and Crohn’s disease patients than controls (417.714 ± 250.37 and 466.071 ± 249.96 vs. 264.75 ±
138.65 pg/ml; p < 0.05). A negative correlation between beta-crosslaps concentration and the femoral and radius t-
scores was evident in microscopic colitis patients.
Conclusions: Low bone mass is frequent in microscopic colitis, and alterations to bone metabolism are similar to
those present in Crohn’s disease. Therefore, microscopic colitis-associated osteopenia could be a significant
problem in such patients.
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Background
Microscopic colitis (MC) is defined by chronic, watery
diarrhoea, abdominal pain and weight loss. However,
macroscopically normal colonic mucosa is evident on
radiological and endoscopic examination, and micro-
scopic examination is required for the detection of diag-
nostic histopathological features [1,2]. MC normally
occurs in middle-aged patients, with a peak incidence in
individuals aged approximately 65 years. The annual
incidence of MC is between four and six per 100,000
individuals. However, the significance of these morpho-
logically distinct diseases is underestimated in daily clin-
ical practice and the pathogenesis underlying MC has
yet to be elucidated. Abnormal collagen metabolism [3],
bacterial toxins [4] and drugs [5] could be responsible
for mucosal injury in MC, although the colonic mucosa
appears normal on colonoscopy examination and diag-
nosis is established using histology.
Two types of MC were initially described more than
30 years ago [6,7]. Collagenous colitis (CC) is defined by
a sub-epithelial collagen layer wider than 10 μm [8].
Diagnostic criteria for lymphocytic colitis (LC) are more
than 10 [9] or 20 [10] intraepithelial lymphocytes (IEL)/
100 epithelial cells of the colonic mucosa. Microscopic
colitis is thought to be a multifactorial disease but the
exact cause is unknown. A high incidence in families
suggests a degree of genetic susceptibility [11,12]. There
is a high incidence of spontaneous resolution of symp-
toms, and budesonide is the drug of choice for first-line
treatment in patients with severe symptoms [13].* Correspondence: mihpal@yahoo.co.uk
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A relationship between MC and members of the clas-
sic inflammatory bowel disease (IBD) group including
Crohn’s disease (CD) and ulcerative colitis (UC) is based
on epidemiological, pathological and clinical associa-
tions. Several case reports demonstrate that MC can
progress to IBD [14-16]. However, a large retrospective
analysis demonstrated no association between the pre-
sence of MC and progression to IBD [9]. Olesen et al.
demonstrated that 12% of patients with LC reported a
family history of other bowel disorders including IBD,
celiac disease and CC [17].
Decreased bone mineral density (BMD) is a common
complication of IBD and is present in 30-77% of cases
[18,19], predominantly in patients suffering from CD
[20]. Compared to healthy controls, individuals suffering
from CD have a relative risk of vertebral and hip frac-
ture of 1.59 and 1.72, respectively [21]. Recent data indi-
cate that low bone mass associated with CD correlates
with the basic pathology of CD rather than malabsorp-
tion or complications of steroid treatment [22,23].
There are currently no studies concerned with possi-
ble alterations in bone metabolism in MC patients. The
aim of this study was to evaluate the bone density and
bone metabolism in patients with MC. The secondary
aim was to compare the alterations in bone metabolism




Fourteen MC patients (12 women and two men with a
mean age of 49.79 ± 13.06 years) were included in the
study. Ten were diagnosed with LC and four with CC.
Enrolment criteria included asymptomatic patients who
had not taken medication for six weeks prior to com-
mencement of the study. Those patients who had been
subjected to treatment with budesonide for longer than
eight weeks, or within six weeks prior to enrolment in
the study, were excluded from participating. The short
plasma half-life of budesonide (1.5-3.5 hours) [24], the
24 hours duration of effects and the first pass effects of
the drug were taken into consideration to define the
wash-out period. Remission during MC was defined as
two or less bowel movements per day without taking
medication. Remission had been achieved using budeso-
nide during the history of these patients; none of the
enrolled patients had been previously treated with sys-
temic steroids. The presence of celiac disease was
excluded using serology (tissue transglutaminase and
endomysial antibody) and duodenal histology. Lympho-
cytic colitis was defined as more than 10 IELs/100
epithelial cells situated in the mucosa, and the diagnos-
tic criterion for CC was a subepithelial collagen layer
wider than 10 μm.
Control groups
Twenty-eight healthy persons (HC) and 28 CD patients
matched for age, gender and postmenopausal state were
enrolled as controls. CD patients were in remission as
defined by the Crohn’s disease activity index (CDAI <
150) [25], and had been steroid free for one year.
Azathioprine up to 2.5 mg/body weight kg and mesala-
zine up to 4 g daily was permitted as a maintenance
therapy for CD patients. None of the participants had
the stricturing or penetrating (Vienna Classification B2
or B3) types of the disease [26]. The members of the
HC group were matched for age, gender and menopau-
sal status to the MC patients. Subjects provided written
informed consent, and the study protocol was approved
by the regional and institutional committee of science
and research ethics (SE-106/2007).
Demographical data, significant medical history (locali-
zation and duration of disease, surgical history and drug
use), risk factors for osteoporosis (body mass index,
menopausal state, smoking status, family history for
osteoporosis and previous low trauma bone fracture)
were recorded. Patients taking medications that affected
vitamin K metabolism were not eligible to participate in
the study.
Bone mineral density measurements
Bone mineral density (BMD) measurements were per-
formed using dual-energy X-ray absorptiometry of the
lumbar spine (L2-L4), the left femoral neck and the
non-dominant radius using a Hologic QDR 4500C
instrument (Hologic, Waltham, MA). For analysis, v.
9.03D software was used. Z-scores were calculated
according to the manufacturer’s reference curves (the
number of standard deviations (SD) from age- and sex-
matched healthy controls). The third National Health
and Nutrition Examination Surveys (NHANES III) nor-
mative data were used as a reference database for
femoral bone density measurements. World Health
Organization (WHO) criteria for low BMD were applied
for this analysis [27]. Low bone mass and osteoporosis
were defined as a BMD t-score below -1 and below -2.5,
at the lumbar spine or the femoral neck, respectively.
Quality control was maintained by carrying out daily
scanning of an anthropometric spine phantom. The
coefficient for the variation of BMD measurements on
the spine phantom over a period of four years was
0.35%.
Parameters of bone metabolism
Serum calcium (normal: 2.25-2.61 mmol/l), parathyroid
hormone (normal: 10-65 pg/ml) and thyroid stimulating
hormone (normal: 0.3-3.3 mU/L) levels were determined
before the study commenced to exclude the presence of
other types of metabolic bone diseases.
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Fasting blood samples for evaluating markers of bone
metabolism were taken between 7 and 8 a.m. Osteocal-
cin (OC) is a bone-specific calcium binding protein pro-
duced by osteoblasts during bone synthesis, and serves
as a good marker for bone formation. After release, it
accumulates in the bone matrix and proportional
amounts leak into the blood stream [28]. More than
90% of the organic bone matrix consists of type I col-
lagen. During certain physiological and pathological pro-
cesses, a degradation product of mature type I collagen,
beta-crosslaps (bCL), is released into the bloodstream.
Accordingly, bCL is a useful marker for monitoring the
process of bone resorption [29].
Serum OC and bCL levels were measured using an
electrochemiluminescence immunoassay (Elecsys N-
MID Osteocalcin and Elecsys b-CrossLaps, Roche, Nut-
ley, NJ). The OC immunoassay detects a stable 43
amino acid fragment of the N-terminal end (N-MID
fragment). The immunoassay was based on monoclonal
antibodies against epitopes located on the stable frag-
ment. The normal concentrations in the serum were 0-
320 pg/ml for bCL and 20-48 ng/ml for OC.
Statistics
Calculations were performed using SPSS statistics 15.0
software. Paired and independent sample Student’s t-
tests, Pearson correlations and chi-square tests were
applied. The results were presented as mean ± SD.
Results were considered significant when p < 0.05.
Results
Major clinical characteristics of the age, gender and
postmenopausal status matched groups are presented in
Table 1.
Bone density parameters
Low bone mass was detected in 57%, 46% and 10.7% of
MC patients, CD patients and the HC group, respec-
tively (Table 2.). Incidence of low bone mass was signifi-
cantly lower in MC and CD patients than in the HC
group (p < 0.01). One of 14 patients with MC had
osteoporosis (t-score < -2.5), while seven had osteopenia
(t-score < -1.0). Five CD patients had osteoporosis and
12 had osteopenia, according to the WHO criteria; three
patients from the HC group had osteopenia. BMD was
lower at the femoral neck in MC and CD patients than
in healthy controls (HC).
There was no significant difference between the
femoral neck BMD levels from MC and CD patients.
Bone density of the lumbar spine in MC patients was
lower than the HC group, but higher than CD patients.
BMD measured at the non-dominant radius was lower
in MC patients than in the HC group and CD patients.
Femoral and radius t-score values were lower in MC
patients than in controls (Table 3).
Bone metabolism parameters
The direction of bone metabolism was evaluated by
detecting the bone resorption and formation markers,
bCL and OC (Figure 1). The mean bCL concentration
was higher in MC patients and CD patients than in the
HC group. The rate of bone resorption, reflected by the
serum concentration of bCL, was more pronounced in
CD patients. There was a negative correlation between
the bCL concentration and the femoral and radius t-
score values in MC patients (-0.8 and -0.77, respectively,
p < 0.05) and CD patients (-0.83 and -0.79, respectively,
p < 0.05). Significantly higher serum concentrations of
the bone formation marker OC were measured in MC
and CD patients than in the HC group. However, the
mean concentration of OC was within the normal range
in each group.
Risk factors for low bone mass
American College of Gastroenterology and American
Gastroenterology Association guidelines recommend
screening IBD patients with DEXA if they have one of
the following risk factors: postmenopausal state, ongoing
corticosteroid treatment, cumulative prior use of corti-
costeroids exceeding three months, history of low
trauma fractures, or aged over 60 years [30,31]. CD and
MC patients and HC subjects were monitored for these
risk factors. Other risk factors including family history
for low bone mass, smoking status and BMI were also
Table 1 Clinical characteristics of patient groups
Microscopic colitis
(10 LC and 2 CC)
Crohn’s disease
duration of disease (years) 4.33 ± 1.66 ns. 5.03 ± 3.53
actual symptoms (number of liquid stools/day) 1.41 ± 0.66 ns. 1.37 ± 0.49
budesonide in the past 11/14 (78.5%) p < 0.01 11/28 (39.28%)
systemic steroid ever none 14/28 (50%)
actual immunosuppressants none 9/28 (32.14%)
Subjects in the healthy control (HC) group had not been treated with medications containing steroids or immunosuppressants, and they were symptomless. The
results are presented as mean ± standard deviation; Student’s t-tests were applied for statistical analysis. (LC = lymphocytic colitis, CC = collagenous colitis, ns =
not significant.)
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evaluated. There was no significant difference in the
BMI (23.45 ± 8.56 vs. 24.23 ± 7.89 and 25.34 ± 12.4 kg/
m2 in CD, MC and HC, respectively), smoking status (5/
14, 12/28 and 13/28 in MC, CD and HC groups; respec-
tively) and family history for osteoporosis (5/14, 11/28
and 13/28 in MC, CD and HC groups; respectively).
Results of the risk assessment are presented in Figure 2.
There was no significant difference in the BMD of MC
patients with or without associated risk factors (Figure
3). Previous steroid therapy is one of the most impor-
tant risk factors for bone loss. Therefore, the bone den-
sities of MC patients with or without previous short
term budesonide therapy were compared. Lumbar and
femoral BMD were similar in patients who had or had
not been treated with budesonide (0.82 ± 0.09 g/cm2 vs.
0.86 ± 0.43 g/cm2, ns; and 0.89 ± 0.04 vs. 0.99 ± 0.49 g/
cm2, ns; respectively). Femoral and lumbar T- scores for
budesonide naïve MC patients were low (-1.68 ± 0.16
and -1.7 ± 0.98).
The serum calcium concentrations of the MC, CD and
HC groups (2.36 ± 0.08 mg/ml, 2.42 ± 0.11 mg/ml and
2.39 ± 0.09 mg/ml) remained unchanged, and the para-
thyroid hormone level was in the normal range in
patients with MC (36.64 pg/ml).
Discussion
There are no available data regarding alterations in bone
metabolism as a complication of MC. The results pre-
sented herein suggest decreased bone density in a
cohort of MC patients with no clinical signs of
malabsorption.
Bone mass was decreased to the same extent in the
MC group and the CD group that had been matched
for age, gender and menopausal status. Considering the
similarly decreased BMD ratios in the MC and CD
groups (57% vs. 46% respectively), and taking into con-
sideration that the incidence of MC is underestimated
in daily clinical practice, it is proposed that low bone
mass is a common occurrence in patients with undiag-
nosed MC who suffer from chronic diarrhoea.
Bone density parameters of patients with MC were
independent from coexisting risk factors including pre-
vious short term budesonide therapy. Based on these
data, a common pathogenic factor is proposed for MC
and the associated bone loss.
The pathophysiology of low bone mass in gastrointest-
inal diseases is different from senile or postmenopausal
osteoporosis. Accelerated bone resorption - so-called
uncoupling - is responsible for low bone mass in CD
[32]. It has been demonstrated that serum markers for
bone formation and bone resorption are higher in CD
than HC [33]. The ratio of bone resorption and bone
formation markers was similar in MC and CD patients.
Serum concentrations of bCL were doubled in MC and
CD patients compared with the HC group. Compensa-
tory elevation of the bone formation marker OC was
more modest in MC and CD patients than the HC
group, without exceeding the normal range. There was a
negative correlation between the bCL concentration and
femoral or radius t-score values in MC patients, demon-
strating a pathogenic relationship between DEXA and
the laboratory measurements.




Femoral BMD (g/cm2) 0.852 ± 0.165** ns. 0.807 ± 0.136** 1.056 ± 0.126
Lumbar BMD (g/cm2) 0.928 ± 0.156 p < 0.05 0.847 ± 0.112* 0.949 ± 0.112
Non-dominant radius BMD (g/cm2) 0.565 ± 0.093* ns. 0.672 ± 0.056* 0.667 ± 0.072
Femoral t-score -0.638 ± 1.437* ns. -0.607 ± 1.09 -0.211+1.053
Lumbar t-score -1.203 ± 1.42 ns. -1.390 ± 1.124 -1.328 ± 1.041
Radius t-score -1.37 ± 1.135* ns. -1.090 ± 1.236* -0.882 ± 1.106
(BMD: bone mineral density, MC: microscopic colitis, CD: Crohn’s disease; HC: healthy controls; paired and independent sample Student’s t-tests were applied. The
results are presented as mean ± standard deviation; * = p < 0.05 and ** = p < 0.01 compared to HC, ns = not significant.)




incidence of low bone mass 57%** ns. 46%** 10,7%
osteoporosis 1 (7%) ns. 5 (17.8%) 0
osteopenia 7 (50%)** ns. 12 (42%)** 3 (10.7%)
(MC: microscopic colitis, CD: Crohn’s disease; HC: healthy controls; paired and independent sample Student’s t-tests were applied. The results are presented as
mean ± standard deviation; * = p < 0.05 and ** = p < 0.01 compared to HC, ns = not significant.)
Lőrinczy et al. BMC Gastroenterology 2011, 11:58
http://www.biomedcentral.com/1471-230X/11/58
Page 4 of 8
Bone mineral content was significantly lower in parts
of the skeleton with a high cortical versus trabecular
bone ratio in MC patients; BMD was more profoundly
decreased in the femoral neck and non-dominant radius
than in the lumbar spine. The mineral content of these
regions was similar in MC and CD patients in the pre-
sent study; however, a lower BMD was evident at the
lumbar spine of CD patients.
Thyroid and parathyroid hormones can affect the two
compartments of bone differently: the loss of cortical
bone is characteristic of hyperthyroidism and hyperpar-
athyroidism. Normal levels of thyroid stimulating hor-
mone, free thyroid hormones, serum calcium and
parathyroid hormones exclude a role for these factors in
cortical bone loss of the patients in this study.
No data are available to describe the various regula-
tion of bone homeostasis in the cortical and trabecular
bones of IBD patients. However, it is known that factors
including sex hormones [34] and their receptors [35]
have different impacts on cortical and trabecular bones.
Hypogonadism is a complication of inflammatory bowel
disease, but a pathogenic role for gonad dysfunction has
not been proven in regard to the altered bone metabo-
lism in IBD [36,37].
A major limitation of this study is the low number of
MC patients; there was no possibility of performing sub-
group analysis in this small cohort. Data concerning LC
and CC patients were analyzed together as histology is
the only relevant difference between these two types of
MC. Furthermore, the mean age of patients with MC is
Figure 1 Serum beta-crosslaps and osteocalcin concentrations were higher in microscopic colitis and Crohn’s disease patients than in
healthy controls. (OC: osteocalcin, bCL: beta-crosslaps, MC: microscopic colitis, CD: Crohn’s disease, HC: healthy control; paired and independent
sample Student’s t-tests were applied. The results are presented as mean ± standard deviation; ns: not significant.)
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Figure 2 Risk factors regarding low bone mass occur with a similar frequency among patients with Crohn’s disease, microscopic
colitis and healthy subjects. Current steroid therapy is a risk factor for low bone mass, but this kind of medication was an exclusion criterion
in this study. (MC: microscopic colitis, CD: Crohn’s disease, HC: healthy control; paired and independent sample Student’s t-tests were applied.
The results are presented as percentage, BMD results are presented as mean ± standard deviation; ns: not significant.)
Figure 3 Bone mass does not differ in microscopic colitis patients, with or without known risk factors for osteoporosis. There was one
low trauma fracture among patients with microscopic colitis; therefore, it was not possible to perform comparisons with regard to this risk
factor. The black line signifies the normal value for bone mineral density. (BMD: bone mineral density, OP: osteoporosis; results are presented as
g/cm2, numbers situated above the bars represent the level of significance between patients with or without risk factors. Paired and
independent sample Student’s t-test were applied for statistical analysis.)
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similar to the perimenopausal age and to the first post-
menopausal decade; therefore, low BMD in patients
with chronic diarrhoea is not a specific indicator of defi-
nitive colonic disease. It is suggested that patients with
chronic diarrhoea undergo a biopsy during colonoscopy;
a specific request to the pathologist should be made to
consider the diagnosis of MC. Densitometry should only
be performed on patients with histologically confirmed
MC.
Conclusion
The present study demonstrates that bone loss can be
an important problem in MC. A similarly decreased
BMD was observed in patients with MC and CD. Low
bone mass was detected in the femur and radius, and
these bones contain more cortical than trabecular bone.
Uncoupled bone remodelling was demonstrated in MC,
with bone resorption demonstrated to exceed compen-
satory bone formation. The current findings are similar
to the changes observed in bone homeostasis in CD.
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